一分钟看懂
这是一项关于非小细胞肺癌的III 期研究，登记的药物或干预包括Telisotuzumab Vedotin；Docetaxel，当前状态为招募中。登记地点显示中国合肥、北京、重庆、福州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Telisotuzumab Vedotin；Docetaxel · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anhui Medical University - Anhui Chest Hospital /ID# 231899 · 合肥
- Beijing Cancer Hospital /ID# 231923 · 北京
- Peking Union Medical College Hospital East - Dongdan Campus /ID# 233175 · 北京
- Beijing Chest Hospital, Capital Medical University /ID# 232202 · 北京
- The First Affiliated Hospital of Chongqing Medical University /ID# 251592 · 重庆
- Fujian Provincial Cancer Hospital /ID# 243134 · 福州
- The First Affiliated Hospital of Xiamen University /ID# 242381 · 厦门
- The First Affiliated Hospital Of Guangzhou Medical University /ID# 238591 · 广州
- Cancer Hospital of Shantou University Medical College /ID# 242182 · 汕头
- Affiliated Hospital of Guangdong Medical College /ID# 233317 · 湛江
- Affiliated Cancer Hospital of Guangxi Medical University /ID# 231855 · 南宁
- People's Hospital of Guizhou Province /ID# 243614 · 贵阳
- Affiliated Hospital of Hebei University /ID# 239586 · 保定
- Harbin Medical University Cancer Hospital /Id# 231941 · 哈尔滨
- The First affiliated Hospital of Nanyang Medical College /ID# 244652 · 南阳
- People's Hospital of Henan Province /ID# 242187 · 郑州
- Henan Cancer Hospital /ID# 239577 · 郑州
- Tongji Hospital Tongji Medical College of HUST /ID# 239575 · 武汉
- Union Hospital Tongji Medical College /ID# 231904 · 武汉
- Hubei Cancer Hospital /ID# 240045 · 武汉
- Hunan Cancer Hospital /ID# 231943 · 长沙
- The Affiliated Hospital of Inner Mongolia Medical University /ID# 242179 · 呼和浩特
- Nanjing Drum Tower Hospital /ID# 231791 · 南京
- Nantong Tumor Hospital /ID# 232424 · 南通
- The First Affiliated Hospital of Nanchang University /ID# 231934 · 南昌
- The Second Affiliated Hospital of Nanchang University /ID# 231935 · 南昌
- Jilin Cancer Hospital /ID# 244702 · 长春
- The Second Affiliated Hospital of Dalian Medical University /ID# 239755 · 大连
- First Affiliated Hospital of China Medical University /ID# 231924 · 沈阳
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 232023 · 西安
- Jinan Central Hospital /ID# 231895 · 济南
- Shandong Cancer Hospital /ID# 251506 · 济南
- LinYi Cancer Hospital /ID# 239713 · 临沂
- Shanghai Chest Hospital /ID# 231897 · 上海
- Shanxi Cancer Hospital /ID# 258674 · 太原
- Sichuan Cancer Hospital /ID# 239707 · 成都
- West China Hospital, Sichuan University /ID# 233703 · 成都
- Tianjin Cancer Hospital /ID# 233176 · 天津
- Tianjin Medical University General Hospital /ID# 231839 · 天津
- The Affiliated Cancer Hospital of Xinjiang Medical University /ID# 240094 · 乌鲁木齐
- Yunnan Cancer Hospital /ID# 251388 · 昆明
- The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 232032 · 杭州
- Zhejiang Cancer hospital /ID# 242476 · 杭州
- Taizhou Hospital of Zhejiang Province /ID# 232021 · 临海
- Ningbo No. 2 Hospital /ID# 242478 · 宁波
公开的入选条件
- * Projected life expectancy of at least 12 weeks.
- * Participants must have c-Met overexpressing non-small cell lung cancer (NSCLC) as assessed by an AbbVie designated immunohistochemistry (IHC) laboratory using the VENTANA MET (SP44) RxDx assay.
- * Archival or fresh tumor material must be submitted for assessment of c-Met protein expression levels during the Pre-Screening period. Tumor material from the primary tumor site and/or metastatic sites are allowed.
- If a participant was prescreened for Study M14-239 but did not enroll, tumor material previously submitted for Study M14-239 may be used for Study M18-868 Pre-Screening upon confirmation from AbbVie that sufficient evaluable tumor material is available (Except
- * A histologically or cytologically documented non-squamous cell NSCLC that is locally advanced or metastatic.
- * A known epidermal growth factor receptor (EGFR) activating mutation status.
- \-- Participants with EGFR activating mutations are not eligible
- * Actionable alterations in genes other than EGFR are eligible.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT04928846；登记信息更新于 2026-09-16。